DAX19.970 -1,4%ESt504.879 -1,6%Top 10 Crypto15,09 -7,4%Dow42.342 ±0,0%Nas19.373 -0,1%Bitcoin93.699 -0,7%Euro1,0360 ±-0,0%Öl72,46 -0,3%Gold2.597 +0,1%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Tesla A1CX3T NVIDIA 918422 Rheinmetall 703000 Amazon 906866 Palantir A2QA4J MicroStrategy 722713 Bayer BAY001 Micron Technology 869020 Volkswagen (VW) vz. 766403 Siemens Energy ENER6Y Atos 877757 Apple 865985 Commerzbank CBK100 Mercedes-Benz Group (ex Daimler) 710000 RWE 703712
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Nach Fed-Leitzinssenkung: DAX schließt unter 20.000 -- US-Börsen kaum verändert -- Rheinmetall erhält Milliarden-Aufträge -- Adnoc erreicht bei Covestro Squeeze-out-Grenze -- Micron, Douglas im Fokus
Top News
Experten zuversichtlich für 2025: Weiteres Wachstum erwartet - Anleger sollten auf NVIDIA-Aktiensplit setzen Experten zuversichtlich für 2025: Weiteres Wachstum erwartet - Anleger sollten auf NVIDIA-Aktiensplit setzen
Reddit-Aktie seit IPO im März +250 Prozent - was für die Reddit-Aktie noch drin ist Reddit-Aktie seit IPO im März +250 Prozent - was für die Reddit-Aktie noch drin ist
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil
Wer­bung
LAST MINUTE GESCHENK mit Herz und Verstand: Der FLEXINVEST JUNIOR-SPARPLAN. Hier KOSTENLOS abschließen & bis zu 75 € Amazon.de* Gutscheine erhalten!

Sanofi Aktie

NeuKaufenVerkaufen
Sanofi Aktien-Sparplan
91,80 EUR +0,54 EUR +0,59 %
STU
91,05 EUR -0,82 EUR -0,89 %
GVIE
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.115,08 Mrd. EUR

KGV20,81Div. Rendite4,19%

WKN920657

ISINFR0000120578

SymbolSNYNF

Sanofi Aktien News

DatumMeistgelesen
PR NewswireDupixent® (dupilumab) Late-breaking Phase 3 Data at the EADV 2022 Congress Showed Significant Improvements in Signs and Symptoms of Prurigo Nodularis
PR NewswireLate-Breaking Dupixent® (dupilumab) Data at ERS 2022 Show Consistent Efficacy and Safety Profile for Up to Two Years in Children Aged 6 to 11 Years with Moderate-to-severe Asthma
GlobeNewswirePress Release: Late-breaking Dupixent® (dupilumab) data at ERS 2022 show consistent efficacy and safety profile for up to two years in children aged 6 to 11 years with moderate-to-severe asthma
GlobeNewswirePress Release: Evolution of the Board of Directors
GlobeNewswirePress Release: XenpozymeTM (olipudase alfa-rpcp) approved by FDA as first disease-specific treatment for ASMD (non-CNS manifestations)
GlobeNewswirePress Release: FDA grants priority review to efanesoctocog alfa for people with hemophilia A
GlobeNewswirePress Release: Sanofi provides update on amcenestrant clinical development program
PR NewswirePublic health experts underscore importance of flu vaccinations to help reduce health inequities among high-risk populations
GlobeNewswirePress Release: Sanofi and Innovent Biologics enter strategic collaboration to accelerate development of oncology medicines and expand presence in China
PR NewswireSanofi appoints new Heads of U.S. General Medicines, and North America Vaccines and Consumer Healthcare
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
GlobeNewswirePress Release: Strong execution in Q2 drives full-year 2022 guidance upgrade and delivers rich R&D news flow in Immunology and Rare Disease
PR NewswireSanofi partners with Howard University in an unprecedented pharmacy fellowship program
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
GlobeNewswirePress Release: Dupixent® (dupilumab) Phase 3 trial shows positive results in children 1 to 11 years of age with eosinophilic esophagitis
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
GlobeNewswirePress Release: Pivotal data demonstrate once-weekly efanesoctocog alfa provides superior bleed protection compared to prior factor prophylaxis
GlobeNewswirePress Release: Fitusiran prophylaxis reduced bleeds by 61% in people with hemophilia A or B, with or without inhibitors, compared to prior factor or bypassing agent prophylaxis
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
GlobeNewswireSanofi Global Health launches nonprofit Impact® brand for 30 medicines in low-income countries
PR NewswireSanofi flu vaccines licensed and approved for 2022-2023 influenza season, including CDC preferred higher-dose vaccines for adults 65+
GlobeNewswirePress Release: Xenpozyme® (olipudase alfa) approved by European Commission as first and only treatment for ASMD
GlobeNewswirePress Release: Nexviadyme® (avalglucosidase alfa) approved by European Commission as a potential new standard of care for the treatment of Pompe Disease
GlobeNewswireAvailability of the Q2 2022 Memorandum for modelling purposes
GlobeNewswirePress Release: Sanofi-GSK first to report a successful efficacy study against Omicron with COVID-19 Beta-containing vaccine
GlobeNewswirePress Release: Sanofi-GSK next-generation COVID-19 booster delivers strong immune response against variants of concern, including Omicron
GlobeNewswireSanofi launches its first Digital Accelerator fueled by new talent and focused on growth
GlobeNewswirePress Release: FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis
PR NewswireFDA Approves Dupixent® (dupilumab) as First Biologic Medicine for Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis
GlobeNewswireSanofi launches 2022 global Employee Stock Purchase Plan for 86.000 people
GlobeNewswirePress Release: Sanofi grants Regeneron worldwide exclusive license rights to Libtayo® (cemiplimab)
PR NewswireSobi: FDA grants efanesoctocog alfa Breakthrough Therapy designation for haemophilia A
GlobeNewswirePress Release: FDA grants efanesoctocog alfa Breakthrough Therapy designation for hemophilia A
GlobeNewswirePress Release: FDA accepts Dupixent® (dupilumab) for priority review in adults with prurigo nodularis
PR NewswireFDA Accepts Dupixent® (dupilumab) for Priority Review in Adults with Prurigo Nodularis
GlobeNewswirePress Release: Update on Cialis® Rx-to-OTC Switch Actual Use Trial
PR NewswireFDA Approves Dupixent® (dupilumab) as First Treatment for Adults and Children Aged 12 and Older with Eosinophilic Esophagitis
GlobeNewswirePress Release: FDA approves Dupixent® (dupilumab) as first treatment for adults and children aged 12 and older with eosinophilic esophagitis
GlobeNewswirePress Release: Sarclisa® (isatuximab) combination provides unprecedented median progression free survival in patients with relapsed multiple myeloma receiving a proteasome inhibitor therapy
GlobeNewswirePress Release: New nirsevimab data analyses reinforce efficacy against RSV

Sanofi News

Sanofi News: auf dieser Seite finden Sie alle Sanofi News und Nachrichten zur Sanofi Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Sanofi News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Sanofi News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.